Nucleic acids encoding anti-OX40 antibodies

US10626181B2 · kind B2 · utility

Assignees

• Agenus Inc. · US
• Memorial Sloan Kettering Cancer Center · US
• LUDWIG INSTITUTE FOR CANCER RESEARCH LTD · GB

Inventors

• Marc van Dijk · Bosch en Duin, NL
• Ekaterina V. Breous-Nystrom · Basel, CH
• Volker Seibert · Lörrach, DE
• Gerd Ritter · New York, US
• David Schaer · Mamaroneck, US
• Daniel Hirschhorn-Cymerman · New York, US
• Hao Tang · Lexington, US
• Taha Merghoub · New York, US
• David Adam Savitsky · Boxford, US
• Jeremy Dale Waight · Everett, US
• Nicholas Stuart Wilson · Melbourne, AU

Key dates

• Filing date: Apr 15, 2019
• Grant date: Apr 21, 2020
• Expiry date: Apr 15, 2039

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2333/70578
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human OX40 and modulate OX40 activity, e.g., enhance, activate, or induce OX40 activity, or reduce, deactivate, or inhibit OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., enhances, activates, or induces OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., reduces, deactivates, or inhibits OX40 activity.